Search
Amphastar Pharmaceuticals Inc
AMPHAdd to Watchlist
19.640USD
-0.460-2.29%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
876.67MMarket Cap
11.49P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.29%
5 Days
-6.65%
1 Month
+6.45%
6 Months
-25.77%
Year to Date
-26.66%
1 Year
-16.71%
Key Figures
20.350Open
20.350High
315.75KVolume
11.49P/E TTM
6.11P/E Dynamic
--Dividend TTM
0.71%Turnover Ratio
20.100Prev. Close
19.630Low
5.20MTurnover
5.50P/E Static
1.13P/B
0.00%Div Yield TTM
4.84%ROA
31.26452wk High
1.10Volume Ratio
159.52MNet Profit
44.64MShares
1.7095EPS TTM
0.93Beta
10.39%ROE
16.64552wk Low
3.58%Amplitude
41.08%Gross Margin
876.67MMarket Cap
4.20Reward/Risk
2.60%Risk Rate
TradingKey Stock Score of Amphastar Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
Amphastar Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 64 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 22.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amphastar Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Amphastar Pharmaceuticals Inc Highlights
StrengthsRisks
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Fairly Valued
The company’s latest PE is 11.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.15M shares, decreasing 11.16% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 64.40K shares of this stock.
Analyst Rating
Based on
7
analysts
Hold
Current Rating
22.000
Target Price
+6.23%
Upside Space
Amphastar Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amphastar Pharmaceuticals Inc Info
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Ticker SymbolAMPH
CompanyAmphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
Websitehttps://amphastar.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Amphastar Pharmaceuticals Inc (AMPH)?
The current price of Amphastar Pharmaceuticals Inc (AMPH) is 19.64.
What is the symbol of Amphastar Pharmaceuticals Inc?
The ticker symbol of Amphastar Pharmaceuticals Inc is AMPH.
What is the 52-week high of Amphastar Pharmaceuticals Inc?
The 52-week high of Amphastar Pharmaceuticals Inc is 31.26.
What is the 52-week low of Amphastar Pharmaceuticals Inc?
The 52-week low of Amphastar Pharmaceuticals Inc is 16.64.
What is the market capitalization of Amphastar Pharmaceuticals Inc?
The market capitalization of Amphastar Pharmaceuticals Inc is 876.67M.
Is Amphastar Pharmaceuticals Inc (AMPH) currently rated as Buy, Hold, or Sell?
According to analysts, Amphastar Pharmaceuticals Inc (AMPH) has an overall rating of signal_hold, with a price target of 22.00.
What is the Earnings Per Share (EPS TTM) of Amphastar Pharmaceuticals Inc (AMPH)?
The Earnings Per Share (EPS TTM) of Amphastar Pharmaceuticals Inc (AMPH) is 2.10.